- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02052947
Co-LEsions in Alzheimer Disease and Related Disorders (CLEM)
One of the crucial challenges for the future of Alzheimer's disease (AD) therapeutic approaches in elderly is to target the main pathological process responsible for disability and dependency. However, a progressive cognitive impairment occurring after the age of 70 is often related to mixed lesions of neurodegenerative and vascular origins. Whereas young patients are mostly affected by pure lesions, aging favors the occurrence of co-lesions of AD, vascular and Lewy body types. Pure DLB (Dementia with Lewy Body) and AD are distinct disorders but they often coexist in old age patients, the Abeta pathology of DLB/AD cases being different to that observed in patients with AD alone. Vascular dementia (VD) and AD with cerebrovascular disease (AD+CVD) are the leading causes of dementia next to AD alone. Lack of consensus persists about the diagnosis criteria for VD and AD+CVD, due in part to their clinical, pathological heterogeneity and the multiple pathological subtypes.
We do not know the precise role and weight of each brain lesion type in the disability progression in elderly. To target the actual pathological process, we need to disclose the functional weight of AD, Lewy body and vascular lesion types in elderly. Most of the studies report on functional and clinical abnormalities in patients with pure pathologies. Thus, co-morbid processes involved in the transition from an independent functional status to disability in the elderly with co-lesions still remain to be elucidated. Neuropathological examination often performed at late stages cannot answer this question at mild or moderate stages.
Brain MRI, Single Photon Emission Computed Tomography (SPECT) with DaTscan® and CSF biomarkers help routinely in performing the diagnosis of pure or mixed lesions responsible for dementia. The topography of the atrophy in MRI helps to provide information about the etiological diagnosis. Medial temporal lobe atrophy on MRI has good discriminatory power for AD compared to DLB and VD in pathologically confirmed cases. DaTscan® SPECT presents with good sensitivity and specificity at early stages of DLB. The good diagnosis value of CSF biological markers has led recently to their inclusion in the research diagnosis criteria of AD. Low Aβ1-42 and high levels of total tau and hyperphosphorylated tau isoforms appear to be the most sensitive and specific CSF biomarkers. Aβ1-42 is lowered in AD, as well as in other neurodegenerative diseases like DLB, VD. The combination of MRI, particularly medial temporal atrophy measures and vascular lesions on FLAIR MRI sequences, SPECT and CSF biomarkers seem to be of incremental value for the diagnosis AD, VD, DLB and mixed profiles.
The aim of this study is to identify the biomarkers (MRI, SPECT-DaTscan® and CSF), and their combination, that are the most predictive of functional disability in elderly presenting with a progressive cognitive decline related to AD, DLB, VD and all mixed patterns.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nawele Boublay
- Phone Number: +33 0472856302
- Email: nawele.boublay@chu-lyon.fr
Study Locations
-
-
-
Villeurbanne, France, 69100
- Recruiting
- Hopital Charpennes
-
Contact:
- Nawele Boublay
- Phone Number: 00334.27.85.63.02
- Email: nawale.boublay@chu-lyon.fr
-
Principal Investigator:
- Pierre KROLAK-SALMON
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subject aged over 70 years
- Out-patient consulting at one of the Memory Centres participating to the study
- Patients meeting diagnosis criteria for dementia due to Alzheimer's disease (McKhann, Knopman et al. 2011), vascular dementia (NINCDS-AIREN criteria, Roma´n, G. C., Tatemichi, T. K., Erkinjuntti, T., et al. (1993), Lewy body disease (McKeith, Dickson et al. 2005), and patients presenting with mixed signs and symptoms suggesting a combination of these diagnosis
- Mild or moderate dementia stage (MMSE criteria > 15)
- Being affiliated to health insurance
- Patient with sufficient visual, auditory and oral and written French language skills to complete the clinical and neuropsychological evaluations
- Accompanied by a close relation in sufficient contact with the subject to assess their dependency
Exclusion Criteria:
- Patients with psychiatric disorders (Axe 1 DSMIV (Diagnostic and Statistical Manual of Mental Disorders) disease) excepted patients with depressive or anxious disorders stabilized for more than 3 months
- Patients taking any neuroleptic psychotropic medication
- Patients taking other psychotropic medication, with the exception of any antidepressant, hypnotic, anxiolytic, acetylcholinesterase inhibitors or memantine which has been prescribed and stabilised for more than 3 months
- Patients with signs and symptoms suggestive of dementia related to other diseases than AD, vascular and Lewy diseases, or mixed forms
- Patients with other neurological diseases
- Patients with progressive and unstable pathologies which could interfere with the variables under consideration
- Deafness or blindness which could compromise evaluation of the patient
- Patients being not able to undergo DaTscan®: with moderate or severe hepatic or renal impairment, a known hypersensitivity to ioflupane or any of the excipients
- Patient living in an institution
- Patient meeting brain MRI exclusion criteria (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body) or refusing MRI
- Patient being under guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: SPEC-DaTscan
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disability progression
Time Frame: 2 years
|
defined by the Disability Assessment in Dementia (DAD) scale (Gauthier, Gelinas et al. 1997; Gelinas, Gauthier et al. 1999)
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neuropsychological inventory
Time Frame: 2 years
|
For the diagnosis and initial correlation with imaging and CSF markers, o For longitudinal assessments : MMSE (Folstein, Folstein et al. 1975), Batterie Rapide d'Efficience Frontale (BREF) (Dubois, Slachevsky et al. 2000) Adas-Cog (Rosen, Mohs et al. 1984)
|
2 years
|
NeuroPsychiatric inventory
Time Frame: 2 years
|
Inventory described in Cummings, Mega et al. 1994
|
2 years
|
Clinical/serum markers
Time Frame: 2 years
|
Disability progression and cognitive decline
|
2 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Lewy Body Disease
- Cerebrovascular Disorders
Other Study ID Numbers
- 2013.795
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lewy Body Disease
-
University of FloridaNational Institute on Aging (NIA)RecruitingLewy Body Dementia With Behavioral Disturbance | Lewy Body Parkinson Disease | Lewy Body DiseaseUnited States
-
University of PennsylvaniaNational Institute on Aging (NIA)RecruitingParkinson Disease | Lewy Body Dementia With Behavioral Disturbance | Lewy Body Parkinson Disease | Parkinson Disease DementiaUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAlzheimer's Disease (AD) | Lewy Body Dementia (LBD) | Frontotemporal Degeneration (FTD)France
-
University of MichiganNational Institute on Aging (NIA)CompletedLewy Body Dementia With Behavioral Disturbance | Lewy Body Disease | Lewy Body Variant of Alzheimer DiseaseUnited States
-
Eisai Co., Ltd.Completed
-
University of California, San DiegoThe Lewy Body Dementia Association (LBDA)RecruitingDementia With Lewy Bodies | Lewy Body Dementia | Parkinson Disease DementiaUnited States
-
University of MichiganFarmer Family FoundationTerminatedParkinson Disease | Lewy Body Dementia | Parkinson Disease DementiaUnited States
-
Mayo ClinicRecruiting
-
Georgetown UniversityCompletedParkinson's Disease | Parkinson's Disease Dementia | Diffuse Lewy Body DiseaseUnited States
-
William Charles KreislNational Institute on Aging (NIA)CompletedDementia With Lewy Bodies | Parkinson's Disease Dementia | Diffuse Lewy Body DiseaseUnited States
Clinical Trials on SPECT-DaTscan
-
GE Healthcarei3 StatprobeCompletedParkinsonian SyndromesUnited States, France
-
Central Hospital, Nancy, FranceCompleted
-
Assistance Publique - Hôpitaux de ParisAssociation Française contre les Myopathies (AFM), Paris; ARS (Association... and other collaboratorsCompletedAmyotrophic Lateral SclerosisFrance
-
Mayo ClinicEnrolling by invitationDementia | Mild Cognitive Impairment | Parkinsonism | REM Sleep Behavior DisorderUnited States
-
GE HealthcareQuintiles, Inc.; H2O Clinical LLCCompletedParkinson's Disease | Essential TremorUnited States
-
Navidea BiopharmaceuticalsWithdrawn
-
Wisconsin Institute for Neurologic and Sleep Disorders...GE Healthcare; Medical College of Wisconsin; Wisconsin Parkinson AssociationUnknownParkinson Disease | Movement DisordersUnited States
-
Molecular NeuroImagingCompletedAlzheimer Disease | Healthy Volunteers | Progressive Supranuclear PalsyUnited States
-
GE HealthcareCompletedVascular Dementia | Lewy Body Dementia | Alzheimer's | Non-DLB DementiaGermany
-
Ken Marek, MDInstitute for Neurodegenerative DisordersCompletedParkinson DiseaseUnited States, Spain, Israel, Norway, Germany, Italy, United Kingdom, France, Austria, Australia, Greece